A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
- PMID: 19783905
 - PMCID: PMC3720128
 - DOI: 10.4161/cbt.8.20.9810
 
A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
Figures
Comment on
- Cancer Biol Ther. 2009 Oct;8(20):1893-901
 
References
- 
    
- American Cancer Society: Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009. [Last accessed 2009].
 
 - 
    
- Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–54. - PubMed
 
 - 
    
- Chang Q, Chen E, Hedley DW. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol Ther. 2009:8. - PubMed
 
 - 
    
- Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999;59:3581–7. - PubMed
 
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous